Tissue chips - innovative tools for drug development and disease modeling

被引:93
作者
Low, L. A. [1 ]
Tagle, D. A. [1 ]
机构
[1] NIH, Natl Ctr Adv Translat Sci, 6701 Democracy Blvd, Bethesda, MD 20892 USA
关键词
PLURIPOTENT STEM-CELL; ON-A-CHIP; MICROPHYSIOLOGICAL SYSTEM; HUMAN LIVER; REPRODUCTIVE-TRACT; CULTURE; DIFFERENTIATION; ABSORPTION; PLATFORM; DESIGN;
D O I
10.1039/c7lc00462a
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The high rate of failure during drug development is well-known, however recent advances in tissue engineering and microfabrication have contributed to the development of microphysiological systems (MPS), or 'organs-on-chips' that recapitulate the function of human organs. These 'tissue chips' could be utilized for drug screening and safety testing to potentially transform the early stages of the drug development process. They can also be used to model disease states, providing new tools for the understanding of disease mechanisms and pathologies, and assessing effectiveness of new therapies. In the future, they could be used to test new treatments and therapeutics in populations - via clinical trials-on-chips - and individuals, paving the way for precision medicine. Here we will discuss the wide-ranging and promising future of tissue chips, as well as challenges facing their development.
引用
收藏
页码:3026 / 3036
页数:11
相关论文
共 99 条
  • [1] Human Skin Constructs with Spatially Controlled Vasculature Using Primary and iPSC-Derived Endothelial Cells
    Abaci, Hasan E.
    Guo, Zongyou
    Coffman, Abigail
    Gillette, Brian
    Lee, Wen-han
    Sia, Samuel K.
    Christiano, Angela M.
    [J]. ADVANCED HEALTHCARE MATERIALS, 2016, 5 (14) : 1800 - 1807
  • [2] Abilez OJ, 2016, NAT MATER, V15, P259, DOI 10.1038/nmat4583
  • [3] Microfluidic heart on a chip for higher throughput pharmacological studies
    Agarwal, Ashutosh
    Goss, Josue Adrian
    Cho, Alexander
    McCain, Megan Laura
    Parker, Kevin Kit
    [J]. LAB ON A CHIP, 2013, 13 (18) : 3599 - 3608
  • [4] [Anonymous], EXP BIOL MED MAYWOOD
  • [5] Phase II failures: 2008-2010
    Arrowsmith, John
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (05) : 1 - 1
  • [6] TRIAL WATCH Phase III and submission failures: 2007-2010
    Arrowsmith, John
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (02) : 1 - 1
  • [7] Epigenetic Memory and Preferential Lineage-Specific Differentiation in Induced Pluripotent Stem Cells Derived from Human Pancreatic Islet Beta Cells
    Bar-Nur, Ori
    Russ, Holger A.
    Efrat, Shimon
    Benvenisty, Nissim
    [J]. CELL STEM CELL, 2011, 9 (01) : 17 - 23
  • [8] Human Vascular Tissue Models Formed from Human Induced Pluripotent Stem Cell Derived Endothelial Cells
    Belair, David G.
    Whisler, Jordan A.
    Valdez, Jorge
    Velazquez, Jeremy
    Molenda, James A.
    Vickerman, Vernella
    Lewis, Rachel
    Daigh, Christine
    Hansen, Tyler D.
    Mann, David A.
    Thomson, James A.
    Griffith, Linda G.
    Kamm, Roger D.
    Schwartz, Michael P.
    Murphy, William L.
    [J]. STEM CELL REVIEWS AND REPORTS, 2015, 11 (03) : 511 - 525
  • [9] Microfluidic organs-on-chips
    Bhatia, Sangeeta N.
    Ingber, Donald E.
    [J]. NATURE BIOTECHNOLOGY, 2014, 32 (08) : 760 - 772
  • [10] Three-dimensional cell culture: the missing link in drug discovery
    Breslin, Susan
    O'Driscoll, Lorraine
    [J]. DRUG DISCOVERY TODAY, 2013, 18 (5-6) : 240 - 249